Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis

Cardiovascular Research

Volumn 60, Issue 1, 2003, Pages 198-204

  Bea, Florian ^a   Blessing, Erwin ^b   Bennett, Brian J ^a   Kuo, Cho Chou ^a   Campbell, Lee Ann ^a   Kreuzer, Jörg ^b   Rosenfeld, Michael E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Atherosclerosis; Cyclooxygenase 2; Infection inflammation; Macrophages

Indexed keywords

APOLIPOPROTEIN E; BIOLOGICAL MARKER; CELECOXIB; CHOLESTEROL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; THROMBOPLASTIN; ACTIN; ANTIINFLAMMATORY AGENT; ISOENZYME; NITRIC OXIDE SYNTHASE; NOS2 PROTEIN, MOUSE; PROSTAGLANDIN SYNTHASE; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY CALCIFICATION; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; BRACHIOCEPHALIC TRUNK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG EFFECT; ENZYME INHIBITION; HISTOPATHOLOGY; KNOCKOUT MOUSE; LIPID ANALYSIS; MACROPHAGE; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RNA ANALYSIS; RNA ISOLATION; TISSUE NECROSIS; ANIMAL; ARTERIOSCLEROSIS; BLOOD; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT FAILURE;

ACTINS; ANIMALS; ANTI-INFLAMMATORY AGENTS; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; BRACHIOCEPHALIC TRUNK; CHEMOKINE CCL2; CHOLESTEROL; CYCLOOXYGENASE 2; ISOENZYMES; MALE; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFONAMIDES; THROMBOPLASTIN; TREATMENT FAILURE;

EID: 0642312173     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(03)00464-4     Document Type: Article

References (47)

1. Fuster V., Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 90:1994;2126-2146.
2. Hansson G.K. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol. 21:2001;1876-1890.
3. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 91:1995;2844-2850.
4. Schmermund A., Erbel R. Unstable coronary plaque and its relation to coronary calcium. Circulation. 104:2001;1682-1687.
5. Hatsukami T.S., Ross R., Polissar N.L., Yuan C. Visualization of fibrous cap thickness and rupture in human atherosclerotic carotid plaque in vivo with high-resolution magnetic resonance imaging. Circulation. 102:2000;959-964.
6. Bini A., Mann K.G., Kudryk B.J., Schoen F.J. Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol. 19:1999;1852-1861.
7. Burke A.P., Kolodgie F.D., Farb A., Weber D., Virmani R. Morphological predictors of arterial remodeling in coronary atherosclerosis. Circulation. 105:2002;297-303.
8. Dubois R.N., Abramson S.B., Crofford L., et al. Cyclooxygenase in biology and disease. FASEB J. 12:1998;1063-1073.
9. Hinson R.M., Williams J.A., Shacter E. Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc Natl Acad Sci USA. 93:1996;4885-4890.
10. Chandrasekharan N.V., Dai H., Roos K.L., et al. From the cover: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA. 99:2002;13926-13931.
11. Simon L.S. Role and regulation of cyclooxygenase-2 during inflammation. Am J Med. 106:1999;37S-42S.
12. Schonbeck U., Sukhova G.K., Graber P., Coulter S., Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol. 155:1999;1281-1291.
13. Baker C.S., Hall R.J., Evans T.J., et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol. 19:1999;646-655.
14. Cipollone F., Prontera C., Pini B., et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation. 104:2001;921-927.
15. Mukherjee D., Nissen S.E., Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. J. Am. Med. Assoc. 286:2001;954-959.
16. Pitt B., Pepine C., Willerson J.T. Cyclooxygenase-2 inhibition and cardiovascular events. Circulation. 106:2002;167-169.
17. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. New Engl J Med. 343:2000;1520-1528.
18. Burleigh M.E., Babaev V.R., Oates J.A., et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation. 105:2002;1816-1823.
19. Rosenfeld M.E., Polinsky P., Virmani R., et al. Advanced atherosclerotic lesions in the innominate artery of the apoE knockout mouse. Arterioscler Thromb Vasc Biol. 20:2000;2587-2592.
20. Williams H., Johnson J.L., Carson K.G., Jackson C.L. Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 22:2002;788-792.
21. Bea F., Blessing E., Bennett B., et al. Simvastatin promotes atherosclerotic plaque stability in ApoE-deficient mice independently of lipid lowering. Arterioscler Thromb Vasc Biol. 22:2002;1832-1837.
22. Movat H.Z. Demonstration of all connective tissue components in a single section. Arch Pathol. 60:1955;289-295.
23. Mallory F.B. Pathological techniques. 2nd ed. 1942;W.B. Saunders, Philadelphia, PA.
24. Duffy A., Fitzgerald D.J., Belton O.A. Inhibition of cyclooxygenase isoforms and the development of atherosclerosis in the APOE knockout mouse. Circulation. 104:2001;II-64. Abstract.
25. Connolly E., Bouchier-Hayes D.J., Kaye E., et al. Cyclooxygenase isozyme expression and intimal hyperplasia in a rat model of balloon angioplasty. J Pharmacol Exp Ther. 300:2002;393-398.
26. Rosenfeld M., Kauser K., Martin-McNulty B., et al. Estrogen inhibits the initiation of fatty streaks throughout the vasculature but does not inhibit intra-plaque hemorrhage and the progression of established lesions in apolipoprotein E deficient mice. Atherosclerosis. 164:2002;251-259.
27. Eligini S., Brambilla M., Banfi C., et al. Oxidized phospholipids inhibit cyclooxygenase-2 in human macrophages via nuclear factor-kappaB/IkappaB- and ERK2-dependent mechanisms. Cardiovasc Res. 55:2002;406-415.
28. Boring L., Gosling J., Cleary M., Charo I.F. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 394:1998;894-897.
29. Aiello R.J., Bourassa P.A., Lindsey S., et al. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 19:1999;1518-1525.
30. Guha M., O'Connell M.A., Pawlinski R., et al. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood. 98:2001;1429-1439.
31. Bavendiek U., Libby P., Kilbride M., et al. Induction of tissue factor expression in human endothelial cells via CD40 ligand is mediated by AP-1, NF-κB, and Egr-1. J Biol Chem. 277:2002;25032-25039.
32. Toschi V., Gallo R., Lettino M., et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 95:1997;594-599.
33. Niu X.L., Yang X., Hoshiai K., et al. Inducible nitric oxide synthase deficiency does not affect the susceptibility of mice to atherosclerosis but increases collagen content in lesions. Circulation. 103:2001;1115-1120.
34. Detmers P.A., Hernandez M., Mudgett J., et al. Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice. J Immunol. 165:2000;3430-3435.
35. Jocks T., Zahner G., Freudenberg J., et al. Prostaglandin E1 reduces the glomerular mRNA expression of monocyte-chemoattractant protein 1 in anti-thymocyte antibody-induced glomerular injury. J Am Soc Nephrol. 7:1996;897-905.
36. Schneider A., Harendza S., Zahner G., et al. Cyclooxygenase metabolites mediate glomerular monocyte chemoattractant protein-1 formation and monocyte recruitment in experimental glomerulonephritis. Kidney Int. 55:1999;430-441.
37. Martin C.A., Dorf M.E. Differential regulation of interleukin-6, macrophage inflammatory protein-1, and JE/MCP-1 cytokine expression in macrophage cell lines. Cell Immunol. 135:1991;245-258.
38. Peebles R.S. Jr., Dworski R., Collins R.D., et al. Cyclooxygenase inhibition increases interleukin 5 and interleukin 13 production and airway hyperresponsiveness in allergic mice. Am J Respir Crit Care Med. 162:2000;676-681.
39. Takayama K., Garcia-Cardena G., Sukhova G.K., et al. Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem. 277:2002;44147-44154.
40. Wu D., Marko M., Claycombe K., et al., Paulson K.E., Meydani S.N. Ceramide-induced and age-associated increase in macrophage COX-2 expression is mediated through up-regulation of NF-kappa B activity. J Biol Chem. 278:2003;10983-10992.
41. Billack B., Heck D.E., Mariano T.M., et al. Induction of cyclooxygenase-2 by heat shock protein 60 in macrophages and endothelial cells. Am J Physiol Cell Physiol. 283:2002;C1267-C1277.
42. Houliston R.A., Keogh R.J., Sugden D., et al. Protease-activated receptors upregulate cyclooxygenase-2 expression in human endothelial cells. Thromb Haemost. 88:2002;321-328.
43. Ahmad N., Chen L.C., Gordon M.A., Laskin J.D., Laskin D.L. Regulation of cyclooxygenase-2 by nitric oxide in activated hepatic macrophages during acute endotoxemia. J Leukoc Biol. 71:2002;1005-1011.
44. Mitchell R.A., Liao H., Chesney J., et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci USA. 99:2002;345-350.
45. Davies M.J. Going from immutable to mutable atherosclerotic plaques. Am J Cardiol. 88:2001;2F-9F.
46. Miralles M., Wester W., Sicard G.A., Thompson R., Reilly J.M. Indomethacin inhibits expansion of experimental aortic aneurysms via inhibition of the cox2 isoform of cyclooxygenase. J Vasc Surg. 29:1999;884-892.
47. Shankavaram U.T., Lai W.C., Netzel-Arnett S., et al. Monocyte membrane type 1-matrix metalloproteinase. Prostaglandin-dependent regulation and role in metalloproteinase-2 activation. J Biol Chem. 276:2001;19027-19032.